Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
5 papers
This CDC analysis used the 2019–2021 National Health Interview Survey to estimate how common chronic pain is among U.S. adults. In 2021, about 20.9% of adults (51.6 million people) reported pain on most days or every day for the past three months. About 6.9% (17.1 million people) had high-impact chronic…
In a small randomized, double-blind crossover study of 15 men with chronic radicular lower‑limb neuropathic pain, a single sublingual dose of THC (about 15.4 mg on average) reduced pain more than placebo. The amount of pain relief was linked to changes on resting‑state fMRI: reduced connectivity between emotional/cognitive brain areas…
This paper looked at 20 clinical trials to see whether therapies that use psychedelic drugs together with talking therapy can help people who have serious, life‑limiting illnesses. The review found that these therapies often helped with psychological and spiritual problems like anxiety, low mood, and fear of dying. The drugs…
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
Researchers gave a low dose of esketamine through an IV before general anesthesia to 200 adults having planned orthopedic surgery. They compared 100 people who got esketamine with 100 who got a saline placebo. The esketamine group showed smaller rises in inflammatory proteins after surgery, higher levels of antibodies, less…
